Key result
Baseline TTR on acenocoumarol poorly predicts future 180-day anticoagulation control.
Why the study?
The predictive value of a previous TTR for future TTR is not well established, and it is unclear what TTR threshold should prompt clinical action.
Does previous time in therapeutic range (TTR) predict future TTR in patients taking acenocoumarol?
Cohort (n=18,031)
No
Does previous time in therapeutic range (TTR) predict future TTR in patients taking acenocoumarol?
Answers are grounded in this paper and cite their sources.
Previous time in therapeutic range (TTR) is a poor predictor of future TTR in patients taking acenocoumarol, suggesting that past TTR alone may not definitively dictate a change in anticoagulation regimen.
BACKGROUND: The benefit of vitamin K antagonists depends on the time within the therapeutic range (TTR). A patient's previous TTR could be a factor in the decision to change the anticoagulation regimen. However, the predictive value of a previous TTR for a future TTR is not well established, nor is it clear which TTR should prompt action. OBJECTIVES: To investigate the predictive performance of a TTR and identify a threshold below which no recovery of TTR should be expected. PATIENTS/METHODS: From 18 031 patients who used acenocoumarol in a first-line anticoagulation clinic, a TTR was calculated over multiple periods of 90, 180, and 365 days each. We assessed the correlation between baseline and later TTR and the separation between groups by quintile of baseline TTR. We describe the proportion of patients who obtain a TTR≥ 70% conditional on baseline TTR. RESULTS: The correlation between baseline and later TTR was 0.25 (95% confidence interval [CI], 0.24-0.26), 0.27 (95% CI, 0.26-0.28) and 0.34 (95% CI, 0.32-0.35) for analyses over 90, 180, and 365 days. Corresponding c statistics for discrimination by baseline group were 0.60, 0.61, and 0.63. The probability to obtain a TTR ≥70% increased with baseline TTR: from 42% with a baseline TTR of 50%-65% when TTR was 100% (TTR calculated over 180 days). CONCLUSIONS: We conclude that a current TTR hardly predicts a future TTR. Physicians and patients should deliberate together which probabilities to accept, take measures to improve TTR, and consider potential alternatives.
No takes yet. Share an insight, caveat, or question.
Miert et al. (2020) conducted a cohort in Thrombosis prevention or treatment requiring vitamin K antagonist anticoagulation (primarily atrial fibrillation and venous thromboembolism) (n=18,031). Baseline time in therapeutic range (TTR) on acenocoumarol vs. Lower baseline TTR strata / quintiles was evaluated on Prediction of future time in therapeutic range (TTR) from baseline TTR over 180 days (r = 0.27; c-statistic 0.61, 95% CI 0.26-0.28). Baseline time in therapeutic range (TTR) on acenocoumarol poorly predicted future 180-day TTR, with a weak correlation and poor discrimination.
Synapse has enriched 10 related papers. Consider them for comparative context: